



## ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference

Feb 26, 2020 | Press Releases

LYON, France and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present a corporate update at the Cowen and Company 40<sup>th</sup> Annual Health Care Conference on March 2, 2020 in Boston, MA.

### 40<sup>th</sup> Annual Cowen and Company Health Care Conference

Date: Monday, March 2<sup>nd</sup>, 2020  
Time: 12:00pm Eastern Time  
Location: Boston, Massachusetts

### About ERYTECH: [www.erytech.com](http://www.erytech.com)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell's altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

### CONTACTS

**ERYTECH**  
**Eric Soyer**  
CFO & COO

**LifeSci Advisors, LLC**  
**Corey Davis, Ph.D.**  
Investor Relations  
New York, New York

**NewCap**  
**Mathilde Bohin / Louis-Victor Delouvrier**  
Investor Relations  
**Nicolas Merigeau**  
Media relations

+33 4 78 74 44 38  
[investors@erytech.com](mailto:investors@erytech.com)

+1 (212) 915 -2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

+33 1 44 71 94 94  
[erytech@newcap.eu](mailto:erytech@newcap.eu)

PDF available at: <http://ml.globenewswire.com/Resource/Download/e972a5a2-36cb-49b2-9092-3d09ce68c852>



Source: Erytech Pharma S.A.